Scarica l'app Stockscreener
3.01
4.44%
-0.14
Dopo l'orario di chiusura:
3.11
0.10
+3.32%
Precedente Chiudi:
$3.15
Aprire:
$3.15
Volume 24 ore:
1.16M
Relative Volume:
1.17
Capitalizzazione di mercato:
$191.32M
Reddito:
$149.50M
Utile/perdita netta:
$-74.62M
Rapporto P/E:
-2.5429
EPS:
-1.1837
Flusso di cassa netto:
$-82.95M
1 W Prestazione:
+2.38%
1M Prestazione:
-5.35%
6M Prestazione:
+121.32%
1 anno Prestazione:
+104.76%
Intervallo 1D:
$2.97
$3.18
Intervallo di 1 settimana:
$2.90
$3.40
Portata 52W:
$1.185
$3.88
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.01 | 200.21M | 149.50M | -74.62M | -82.95M | -1.1837 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
MacroGenics and Sagard to expand Zynyz royalty purchase agreement - The Pharma Letter
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
MacroGenics expands royalty deal with Sagard for $60M By Investing.com - Investing.com South Africa
MacroGenics (MGNX) price target increased by 50.00% to 6.12 - MSN
MacroGenics Expands ZYNYZ Royalty Agreement for Added Funding - TipRanks
MacroGenics (Nasdaq: MGNX) secures $60M in expanded ZYNYZ royalty deal - Stock Titan
Incyte (INCY) Partners with MacroGenics in Expanded Royalty Agre - GuruFocus
MacroGenics expands royalty deal with Sagard for $60M - Investing.com UK
MacroGenics Expands ZYNYZ Royalty Deal With Sagard Healthcare Partners - Moomoo
Macrogenics and Sagard Healthcare Partners enter into expanded Zynyz® Royalty Purchase Agreement - marketscreener.com
$60M now, up to $20M more: MacroGenics expands ZYNYZ deal - Stock Titan
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement - Yahoo Finance
MSN Money - MSN
MSN - MSN
MacroGenics, Inc. (NASDAQ:MGNX) Short Interest Down 22.5% in April - MarketBeat
MacroGenics gains removal of FDA partial hold on lead program - MSN
MacroGenics (MGNX) price target increased by 11.11% to 4.08 - MSN
B Riley Securities upgrades MacroGenics (MGNX) - MSN
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MacroGenics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
MacroGenics (MGNX) Stock Research | Q4 2025: EPS Beats ForecastsROIC - Cổng thông tin điện tử tỉnh Lào Cai
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MGNX Maintains by Barclays -- Price Target Raised to $6.00 - GuruFocus
Macrogenics Is Maintained at Overweight by Barclays - Moomoo
MacroGenics Inc stock (US5562221046): Is its oncology pipeline strong enough to unlock new upside? - AD HOC NEWS
MacroGenics Nears Key Prostate Cancer Catalyst as Phase 2 Lorigerlimab Trial Completes - TipRanks
FDA Lifts Clinical Hold on MacroGenics Phase 2 Cancer Trial - HarianBasis.co
B. Riley Sees Upside in MacroGenics, Inc. (MGNX) Following Gilead-Driven Sector Activity - Yahoo Finance
MacroGenics (MGNX) Stock: Stabilizing? (Smart Money Outflows) 2026-04-16High Volume Stocks - Cổng thông tin điện tử tỉnh Lào Cai
MacroGenics (MGNX) Stock Take Profit (Momentum Building) 2026-04-15Global Trading Community - Cổng thông tin điện tử tỉnh Tây Ninh
Recap Report: What is the next catalyst for MacroGenics IncQuarterly Profit Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Sentiment Review: Whats the profit margin of MacroGenics Inc2026 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley Securities | MGNX Stock News - GuruFocus
Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley - GuruFocus
Macrogenics Inc Stock Historical Valuations | HAM:M55 - GuruFocus
Macrogenics Inc Stock Intrinsic Values | HAM:M55 - GuruFocus
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):